clinical trial · NCT05156398
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
MigraineRimegepantPlacebo
brief summary
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
started
Feb 28, 2022
primary completion
Mar 27, 2029
completion
Oct 30, 2032
last updated
Sep 28, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol